Acceleron Pharma up 7% on FDA nod for luspatercept

Acceleron Pharma (XLRN +7%) and collaboration partner Celgene (CELG +0.4%) announce FDA approval of Reblozyl (luspatercept-aamt) for the treatment of anemia in adult beta thalassemia patients who require regular red blood cell transfusions.

The companies will co-promote the product in the U.S.

https://seekingalpha.com/news/3517295-acceleron-pharma-7-percent-fda-nod-luspatercept